Literature DB >> 35882694

ASO Author Reflections: Neoadjuvant Treatment for Melanoma-Where Are We Now?

Cimarron E Sharon1, Giorgos C Karakousis2.   

Abstract

Entities:  

Year:  2022        PMID： 35882694     DOI： 10.1245/s10434-022-12308-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   4.339


× No keyword cloud information.
  5 in total

1.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Authors:  Christian U Blank; Elisa A Rozeman; Lorenzo F Fanchi; Karolina Sikorska; Bart van de Wiel; Pia Kvistborg; Oscar Krijgsman; Marlous van den Braber; Daisy Philips; Annegien Broeks; Johannes V van Thienen; Henk A Mallo; Sandra Adriaansz; Sylvia Ter Meulen; Loes M Pronk; Lindsay G Grijpink-Ongering; Annemarie Bruining; Rachel M Gittelman; Sarah Warren; Harm van Tinteren; Daniel S Peeper; John B A G Haanen; Alexander C J van Akkooi; Ton N Schumacher
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

2.  Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Authors:  Elisa A Rozeman; Alexander M Menzies; Alexander C J van Akkooi; Chandra Adhikari; Carolien Bierman; Bart A van de Wiel; Richard A Scolyer; Oscar Krijgsman; Karolina Sikorska; Hanna Eriksson; Annegien Broeks; Johannes V van Thienen; Alexander D Guminski; Alex Torres Acosta; Sylvia Ter Meulen; Anne Miek Koenen; Linda J W Bosch; Kerwin Shannon; Loes M Pronk; Maria Gonzalez; Sydney Ch'ng; Lindsay G Grijpink-Ongering; Jonathan Stretch; Stijn Heijmink; Harm van Tinteren; John B A G Haanen; Omgo E Nieweg; Willem M C Klop; Charlotte L Zuur; Robyn P M Saw; Winan J van Houdt; Daniel S Peeper; Andrew J Spillane; Johan Hansson; Ton N Schumacher; Georgina V Long; Christian U Blank
Journal:  Lancet Oncol       Date:  2019-05-31       Impact factor: 41.316

3.  Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Authors:  Alexander M Menzies; Rodabe N Amaria; Elisa A Rozeman; Alexander C Huang; Michael T Tetzlaff; Bart A van de Wiel; Serigne Lo; Ahmad A Tarhini; Elizabeth M Burton; Thomas E Pennington; Robyn P M Saw; Xiaowei Xu; Giorgos C Karakousis; Paolo A Ascierto; Andrew J Spillane; Alexander C J van Akkooi; Michael A Davies; Tara C Mitchell; Hussein A Tawbi; Richard A Scolyer; Jennifer A Wargo; Christian U Blank; Georgina V Long
Journal:  Nat Med       Date:  2021-02-08       Impact factor: 53.440

Review 4.  Educational Review: Neoadjuvant Approaches to Melanoma.

Authors:  Cimarron E Sharon; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2022-07-18       Impact factor: 4.339

5.  Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

Authors:  Alexander M Menzies; Alexander C J van Akkooi; Judith M Versluis; Noëlle M J van den Heuvel; Irene L M Reijers; Robyn P M Saw; Thomas E Pennington; Ellen Kapiteijn; Astrid A M van der Veldt; Karijn P M Suijkerbuijk; Geke A P Hospers; Elisa A Rozeman; Willem M C Klop; Winan J van Houdt; Karolina Sikorska; Jos A van der Hage; Dirk J Grünhagen; Michel W Wouters; Arjen J Witkamp; Charlotte L Zuur; Judith M Lijnsvelt; Alejandro Torres Acosta; Lindsay G Grijpink-Ongering; Maria Gonzalez; Katarzyna Jóźwiak; Carolien Bierman; Kerwin F Shannon; Sydney Ch'ng; Andrew J Colebatch; Andrew J Spillane; John B A G Haanen; Robert V Rawson; Bart A van de Wiel; Lonneke V van de Poll-Franse; Richard A Scolyer; Annelies H Boekhout; Georgina V Long; Christian U Blank
Journal:  Nat Med       Date:  2022-06-05       Impact factor: 87.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.